AlphaMol combines computational methods and in-house cutting-edged biotechnology, aiming at advancing pre-clinical GPCR drug discovery in an ultimately efficient way. AlphaMol has invented three first-in-class PCC within 3-9 months, which usually takes 5-7 years to achieve via traditional way.
G protein-coupled receptors (GPCRs) are the most important drug targets. About 40% of the marketed drugs are targeting at GPCRs. Almost all important diseases are related to GPCRs directly, including Alzheimer's disease, cancer, diabetes, pain, depression, auto-immune, infections and many others.
AlphaMol established a dedicated GPCR-purposed platform for drug discovery. In the GPCR-DOCK 2021 global contest, AlphaMol defeated Google's AlphaFold2 for the five nominated targets, with 60% higher accuracy. In 2022, AlphaMol obtained the best outstanding award in NVIDIA Inception contest for startups. In the same year, both co-founders of AlphaMol, Prof. Shuguang Yuan and Prof. Horst Vogel were in the list of "top 2%" scientists in the world.
Company Details
- Employees
- 3
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.alphamol.com
Alphamol Science Ltd Questions
Alphamol Science Ltd's website is http://www.alphamol.com
Alphamol Science Ltd's LinkedIn profile is https://www.linkedin.com/company/alphamol
Alphamol Science Ltd has
3 employees.
View email and phone details for 3
employees at Alphamol Science Ltd.
Alphamol Science Ltd's industry is
Biotechnology Research
Alphamol Science Ltd's top competitors are
Bristol Myers Squibb,
上海长森药业有限公司,
Actelion (Now Janssen Pulmonary Hypertension),
Progeneer,
Efficraft,
Peptone,
Ancora.ai,
Pharmadeer,
Koios Care,
Basel Area Business & Innovation.
Alphamol Science Ltd's categories are Biotechnology Research
